The patch itself is a small square studded with a 10 by 10 array of conical microneedles, each roughly 800 micrometers tall with a base diameter of about 300 micrometers. What makes the device remarkable is not its size but its internal architecture. Every needle is built in two concentric layers, fabricated through a stepwise centrifugal casting process into a silicone mold. The outer shell is made of methacrylated hyaluronic acid, or HAMA, a hydrophilic polymer that is photocrosslinked under 425-nanometer light. The inner core, along with the backing layer of the patch, is made of chitosan, a naturally occurring cationic polysaccharide. Each compartment carries a different therapeutic payload: the shell holds MCC950, a selective small-molecule inhibitor of the NLRP3 inflammasome, while the core carries basic fibroblast growth factor, or bFGF, a potent driver of blood vessel formation.

The choice of NLRP3 as the early target reflects a growing consensus about what goes wrong after a heart attack. When cardiomyocytes die from oxygen starvation, they release danger-associated molecular patterns that activate the NLRP3 inflammasome, a multiprotein immune sensor found in cardiomyocytes, fibroblasts, and infiltrating immune cells. Once assembled, this complex triggers caspase-1, which matures the inflammatory cytokines interleukin-1 beta and interleukin-18, amplifying cell death, fibrosis, and adverse ventricular remodeling. MCC950 works by blocking the oligomerization of ASC, the adaptor protein that assembles the inflammasome, and previous animal studies have shown it can shrink infarct size and preserve cardiac function. But timing is everything: NLRP3 activation peaks in the acute window, so delayed or systemic dosing risks missing the therapeutic moment while exposing the rest of the body unnecessarily.

The release kinetics engineered into the patch address that problem directly. Under acidic conditions mimicking the ischemic microenvironment, the MCC950 surrogate released about 23 percent of its payload within 15 minutes and 79 percent within one hour, with near-complete release by three days. That burst profile aligns precisely with the acute inflammatory phase. The bFGF story is entirely different: confined within the chitosan core, whose protonated amino groups bind the growth factor electrostatically, only 34.5 percent had escaped by day one, 50.2 percent by day four, and roughly 94 percent over 15 days. This sustained trickle is exactly what bFGF needs, since protein therapeutics degrade rapidly and vanish from tissue without a protective carrier. The researchers also found that release was faster at pH 5.4 than at physiological pH 7.4, suggesting the acidic infarct environment itself may help accelerate early drug delivery.

Mechanically, the patch proved robust enough for cardiac work. Compression testing showed the core-shell design withstood a maximum force of 30 newtons before complete insertion, thanks largely to the stiffness contributed by the crosslinked HAMA network. When a fluorescently labeled patch was pressed onto freshly excised rat left ventricular tissue, confocal imaging detected tracer deposited to a depth of approximately 700 micrometers, confirming that the needles physically penetrate the superficial myocardium rather than merely resting on its surface. That penetration matters therapeutically: it shortens the diffusion distance drugs must travel, improves local retention, and avoids the leakage and uneven distribution that plague direct intramyocardial injection, while keeping systemic exposure far lower than oral or intravenous routes would allow.

In laboratory dishes, the dual-loaded patch showed both faces of its therapeutic personality. When H9C2 rat cardiomyoblast cells were deprived of oxygen and glucose for eight hours, a condition that mimics ischemia, apoptosis climbed to 23.11 percent. Treatment with the MCC950-loaded patch cut that figure to 6.91 percent, and the dual-loaded version lowered it further to 6.03 percent. Molecular analysis confirmed the mechanism: levels of NLRP3, caspase-1, IL-1 beta, and IL-18 all dropped sharply in the MCC950-containing groups, while bFGF alone had little anti-inflammatory effect. On the vascular side, the story reversed. Human umbilical vein endothelial cells exposed to bFGF-containing patches proliferated vigorously, reaching nearly 180 percent viability at 72 hours, closed scratch wounds at rates of 94 to 96 percent within 24 hours, and formed dense capillary-like networks on Matrigel. Crucially, co-delivery of MCC950 did not blunt bFGF activity, and vice versa.

The decisive test came in rats subjected to permanent ligation of the left anterior descending coronary artery, a standard model of severe myocardial infarction. Patches were applied directly to the epicardial surface immediately after ligation, and the animals were followed for four weeks. Seven days after treatment, infarct tissue from rats receiving the dual-loaded patch showed markedly suppressed expression of NLRP3, IL-1 beta, and IL-18, and their serum levels of both cytokines were significantly reduced compared with untreated infarcted animals. Immunostaining revealed that NLRP3 suppression deepened between day 7 and day 28, while TUNEL staining showed apoptotic cell death falling steadily in the dual-treated group, evidence of a sustained protective effect rather than a transient pharmacological blip.

The functional outcomes were striking. By day 28, rats treated with the dual-loaded patch had a left ventricular ejection fraction of 69.4 percent and fractional shortening of 39.8 percent, compared with just 34.5 percent and 17.0 percent in untreated infarcted controls. Single-agent patches helped, but consistently less. End-diastolic and end-systolic volumes, which balloon as the ventricle dilates and remodels, were best preserved in the dual-treated group. Histology told the same story: hematoxylin and eosin staining showed better-preserved tissue architecture, Masson’s trichrome staining revealed the smallest fibrotic area of any treatment group, and ventricular wall thinning was markedly alleviated. Markers of angiogenesis, CD31 and alpha-SMA, were most strongly expressed in the dual-loaded group at day 28, indicating both new vessel formation and vascular maturation, while Ki67 staining pointed to a persistently active reparative microenvironment.

The authors are candid about the limitations that stand between this patch and the clinic. The in vitro release studies were conducted in static buffer conditions that cannot fully reproduce the dynamic pH, enzymatic activity, and interstitial flow of a living infarct, and the H9C2 cell line, being immature cardiomyoblasts, may not faithfully represent adult human cardiac inflammatory responses. The 28-day rat study leaves open questions about long-term biodegradation of the HAMA and chitosan matrix, potential residue persistence, and systemic biosafety. Perhaps most practically, the patch was implanted through open-chest surgery, a procedure that would need to be adapted to minimally invasive thoracoscopic or catheter-based delivery for real patients. Manufacturing reproducibility, sterilization, storage stability, and regulatory consistency also remain to be addressed.

Even so, the conceptual advance is considerable. Most biomaterial platforms for cardiac repair release their cargoes simultaneously or with little temporal distinction, ignoring the fact that infarct healing is a staged biological program in which the priorities of week one are nearly opposite to those of week four. By encoding a therapeutic sequence directly into material architecture, a fast-hydrating shell paired with a slow-releasing core, the researchers have demonstrated that drug presentation can be synchronized with disease-stage biology rather than fighting against it. The same logic, the authors note, could extend beyond cardiology to any condition marked by a transition from acute inflammation to regenerative remodeling, from diabetic wounds to spinal cord injury. For the millions of heart attack survivors who face progressive heart failure despite reperfusion therapy, a tiny two-layer needle array that knows which drug to release, and when, offers a glimpse of what precision biomaterial therapy might look like.

Subject of Research: A core-shell microneedle patch for sequential anti-inflammatory and pro-angiogenic drug delivery to repair heart tissue after myocardial infarction

Article Title: A core-shell microneedle patch coordinates early anti-inflammatory modulation and sustained pro-angiogenic stimulation for cardiac repair after myocardial infarction

Article References: A core-shell microneedle patch coordinates early anti-inflammatory modulation and sustained pro-angiogenic stimulation for cardiac repair after myocardial infarction. (n.d.). https://doi.org/10.1016/j.mtbio.2026.103704

Image Credits: AI Generated

DOI: 10.1016/j.mtbio.2026.103704

Keywords: myocardial infarction, microneedle patch, NLRP3 inflammasome, MCC950, bFGF, angiogenesis, cardiac repair, drug delivery, hyaluronic acid, chitosan, ventricular remodeling, biomaterials

The biology underlying peripheral nerve repair is intricate. After a nerve is transected, the segment downstream of the cut undergoes Wallerian degeneration, a process in which the axoplasm and axolemma break down and myelin debris accumulates in the injured stump. This debris must be cleared before new axons can grow. Schwann cells, the glial cells of the peripheral nervous system, respond by rapidly de-differentiating into repair-mode cells that secrete pro-regenerative factors, digest myelin through autophagy, recruit macrophages, and form regeneration tracks, known as bands of Büngner, that guide growing axons from the proximal stump back toward their original targets. Macrophages, meanwhile, perform the dual tasks of removing debris and supporting axon elongation. Coordinating all of these players takes time; axons may need up to ten months to reach their target tissues, which is why clinicians have long sought drugs that can safely speed the process.

Neurotrophic factors, the signaling proteins that nurture neuronal survival and growth, have been an obvious place to look. Molecules such as nerve growth factor, brain-derived neurotrophic factor, glial cell line-derived neurotrophic factor, VEGF and IGF-1 have all shown promise in experimental settings. Yet their clinical translation has been hampered by poor pharmacokinetics, high costs and significant side effects. Basic fibroblast growth factor, or bFGF, is one of the most powerful of these agents, secreted by Schwann cells and neuronal populations, and it stimulates the proliferation of neurons, Schwann cells and fibroblasts while playing a pivotal role in nerve and spinal cord repair. But native bFGF has a troubled clinical record. A trial in acute stroke patients failed to demonstrate efficacy and revealed fever, lowered blood pressure, elevated leukocyte counts and potential carcinogenic effects, largely because the growth factor also drives cell proliferation.

SUN11602 was designed to sidestep that problem. It is a small aniline-derivative molecule that mimics the neuroprotective effects of bFGF by engaging the same receptor, FGFR1, a transmembrane tyrosine kinase receptor to which bFGF binds with high affinity. Crucially, SUN11602 activates FGFR1 to induce expression of calbindin-D28k, a calcium-binding protein that helps maintain intracellular calcium homeostasis, without triggering the proliferative activity that makes native bFGF risky. The compound also boasts pharmacokinetics that make it a plausible drug candidate: oral bioavailability above 65 percent in rodents and dogs. Previous studies have suggested neuroprotective effects in models of Alzheimer’s disease, depression, Parkinson’s disease and traumatic spinal cord injury, but its role in peripheral nerve regeneration had not been tested.

To fill that gap, the Messina team used sixteen female Wistar rats and a surgically precise injury model. Under an operative microscope, the median nerve of the left upper limb was exposed at the middle third of the brachium and transected, then repaired with an end-to-end suture using two to three epineurial stitches of 9-0 monofilament nylon, replicating the standard clinical repair technique. Beginning 24 hours after surgery, one group of injured rats received SUN11602 at 2.5 milligrams per kilogram by oral gavage once daily for seven consecutive days, while injured controls received only saline. A sham group underwent incision without nerve section. The dose and route were grounded in earlier in vivo work by the same laboratory, and the study was conducted under Italian and European animal research regulations with approval from the Ministry of Health.

Seven days after suture, the differences between groups were visible under the microscope. Haematoxylin and eosin staining revealed that the injured, untreated nerves had the expected hallmarks of acute Wallerian degeneration: structural disorganization, oedema, vacuolization and early myelin and axonal degeneration. Nerves from the SUN11602-treated animals, by contrast, showed comparatively preserved architecture, with reduced vacuolization and less tissue disarray. In other words, the drug appeared to blunt the secondary damage that typically accompanies the degenerative phase, without abolishing degeneration itself, which the authors emphasize is a physiologically required step for successful regeneration.

The anti-inflammatory effects were equally striking. Toluidine blue staining, which highlights mast cells, showed that injured control nerves accumulated large numbers of these cells in the connective tissue and along axon fibres with irregular morphology and degenerating myelin sheaths. Mast cells congregate near peripheral nerves and are considered key orchestrators of neurogenic inflammation and neuropathic pain. In the SUN11602-treated group, mast cell accumulation was suppressed and axon fibre density was higher. Immunostaining for IBA-1, a marker of activated resident macrophages, and CD68, a marker of pro-inflammatory M1 macrophages that infiltrate the injury site and release cytokines, both showed intense upregulation after nerve transection. SUN11602 treatment significantly attenuated both, suggesting the drug restrains the inflammatory response that can otherwise impede repair in the critical first days after injury.

The compound also appeared to support the rebuilding side of the ledger. Immunofluorescence labeling for S100, a Schwann cell marker, showed more consistent and interconnected stained areas in treated nerves, indicating enhanced Schwann cell proliferation and myelinization. Quantification of myelin basic protein by ELISA confirmed the histological picture: concentrations of MBP were significantly higher in the SUN11602 group than in injured controls, evidence of increased myelin production at the molecular level. MCOLL staining, a histochemical method that distinguishes myelin in blue from collagen fibers in red, allowed the researchers to visualize the nodes of Ranvier and the organization of connective tissue around nerve fibers. Injured control nerves showed marked demyelination and disorganized collagen deposition consistent with fibrosis, whereas treated nerves displayed axonal remyelination and reorganized collagen architecture.

The authors are careful about what these findings do and do not mean. All evaluations were performed at a single early time point, seven days after suture, when axonal regeneration and remyelination are only beginning. The observed attenuation of myelin degradation, they write, should not be read as a global inhibition of Wallerian degeneration; rather, they hypothesize that SUN11602 may selectively reduce secondary or excessive demyelination in spared fibers, a distinction that will require ultrastructural analysis and time-course studies of myelin clearance to confirm. The histological improvements also remain unlinked to functional recovery, since no electrophysiological or behavioral testing was included. Future work, the team notes, should incorporate extended follow-up periods, functional and electrophysiological assessments, and combination strategies such as nerve conduits and biomaterials to better mimic complex clinical conditions.

Even with those caveats, the study adds SUN11602 to a short list of candidates that could reshape how peripheral nerve injuries are treated. Because it is orally bioavailable and lacks the proliferative liabilities of native bFGF, the compound addresses the two biggest obstacles that have kept neurotrophic therapies out of the clinic: delivery and safety. If the early histological benefits observed here translate into sustained axonal regrowth, remyelination and functional recovery in longer studies, an oral pill taken in the days and weeks after nerve repair surgery could become a genuine adjunct to the operating microscope. For now, the message from Messina is a proof of principle: the molecular machinery of nerve regeneration can be pharmacologically tuned, and the earliest, most inflammatory phase of repair may be the best place to intervene.

Subject of Research: Pharmacological enhancement of early peripheral nerve regeneration using the oral FGFR1 agonist SUN11602 in a rat median nerve transection model

Article Title: SUN11602 Accelerates Early Peripheral Nerve Regeneration in an Experimental Median Nerve Transection Model

Article References: Casili, G., Papalia, I., Ardizzone, A., Basilotta, R., Costa, A. L., Titolo, P., Esposito, E., Colonna, M. R., & Galeano, M. (2026). SUN 11602 Accelerates Early Peripheral Nerve Regeneration in an Experimental Median Nerve Transection Model. Journal of Cellular and Molecular Medicine, 30(19), Article e71375. https://doi.org/10.1111/jcmm.71375

Image Credits: AI Generated

DOI: 10.1111/jcmm.71375

Keywords: peripheral nerve injury, SUN11602, FGFR1, bFGF, Schwann cells, Wallerian degeneration, mast cells, macrophages, myelination, median nerve transection, neuroprotection, rat model